Of further interest is the form of the psychoses; the present cases combined with those reported previously have been restricted to 11 paranoid and four manic illnesses. Functional psychoses are, by tradition, broadly divided into schizophrenic and affective groups. Among patients with schizophrenia, however, a subgroup has been postulated with "positive" symptoms associated with acute illness and a good response to dopamine blocking neuroleptics.' Similar drugs are also known to be effective in mania,14 and bromocriptine has been reported to exacerbate manic symptoms.'5 Dopamine receptors may possibly take part in the pathogenesis of both paranoid and manic illnesses despite the traditional diagnostic distinction, and this common pathogenetic mechanism may be the cause of a superficial likeness in aspects of their clinical symptomatology. Although in our group all the women developed paranoid illnesses and the two men became manic, a much larger series would be required to establish any significant sex difference.
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Although the reactions reported above were almost certainly due to the dopamine agonists per se, it must be noted that little is known of the incidence of psychotic symptoms in untreated acromegaly or hyperprolactinaemia. Apart from isolated case reports,"" only generalised anecdotal comment is available. In our series neither endocrine state nor the pattern of response to treatment was predictive of a psychiatric relapse. We believe, in view of the time course of relapse and remission and the relation to drug treatment, that these illnesses were not simply a reflection of the underlying endocrine disorder.
Clearly, these side effects must be recognised in view of the particular strain that may be placed on the patients and their families. Alterations in day to day behaviour, non-compliance with treatment, unusual changes in work or social life, unaccountable moodiness or misery are all suggestive and should alert the physician. The stigma of such illness remains strong, and we cannot absolutely exclude the possibility that some cases have gone unrecognised. Nevertheless, it must be emphasised that only eight out of 600 patients treated with dopamine agonists definitely developed this type of reaction.
Introduction
The amount of bone lost yearly in the period immediately after the menopause approaches 2%. Although this rate then declines, bone loss will reach such a magnitude that by the age of 70 some 40% of women will have had at least one spontaneous postmenopausal fracture.' Hip fracture, the most severe, is associated with a six month mortality of 20%, and the incidence of these fractures seems to be increasing. Postmenopausal age (months) 18 Figure 2 gives the mean percentage changes in bone mineral content and urinary calcium excretion as a function of time. In the three groups the slopes of the regression of bone mineral content on time were -0-43, -0 40, and -0-50, and none was significantly different from the overall slope of -0-42. The corresponding r values were -0-92, -0-99, and -0 99, respectively, compared with an overall value of -099.
There was continuous bone loss in all three groups, the yearly loss reaching 1-9o , 1-6°o, and 2 0°o respectively during the two years (p <0-001). In all three groups calcium excretion rose within three months of starting the daily supplement of 500 mg calcium (p <0-05-0-01). The percentage rise was greatest in group 1, with the lowest calcium intake. After the first three to six months calcium excretion fell (p<0-01-0 001) in all groups, reaching the initial value in groups 2 and 3 after 18 months to two years, but remaining above that value in group 1. When the participants were stratified (into three groups) according to initial calcium excretion rate no differences were seen in the rate of bone loss; nor, when stratified according to the rate of bone loss, were there any differences in the initial or final calcium excretion values, and the estimated dietary calcium intakes were similar in the three groups. 
Discussion
The 103 women in this study were a representative sample of all Danish women in early menopause,3 and the three groups were well matched (tables I and II). We did not measure actual dietary calcium intake; nevertheless, that the estimate obtained by questioning did, to some extent at least, reflect differences in calcium intake is supported by the differences in calcium excretion.
When the participants were stratified according to bone loss no differences in calcium intake or excretion were found; this suggests that other factors determine the rate of bone loss. "Fast losers" may have been inadvertently overrepresented in the high calcium intake group, whereby a possible beneficial effect of calcium would have been masked. This does not seem to have been the case, however, since menopausal age, body weight, alkaline phosphatase activity, and hydroxyproline excretion were identical in the three groups and an increase of these values, among others, characterises fast losers.'4 Moreover, the distribution of fast and slow losers within the three groups did not differ significantly (fig 1) . In the statistical evaluation of bone loss with age we calculated the individual slopes, the slopes of the mean values (fig 2) , and the differences between the initial and final values of bone mineral content (fig 1) . All three types of calculation gave virtually the same results, indicating that the decreases in bone mass during the two years of observation were relatively linear. In all the calculations we took the initial value as 100% and expressed the subsequent measurements as a percentage of that value. Each measurement of bone mineral content was calculated as the mean of 12 scans, which partly accounts for the high precision and makes several baseline measurements unnecessary.
Heaney et al reported that calcium balance and intake are related, and that in postmenopausal women a calcium intake above 1400 mg daily will lead to a positive calcium balance.'0 According to their results the balance should have been negative in our group 1, almost zero in group 2, and positive in group 3. Heaney et al"5 and others'6 17 also claimed that calcium supplementation leads to increased bone mass. Irrespective of calcium intake identical and significant reductions in bone mass were seen in all three groups in our study (fig 2) . Only 14 of the 103 women actually showed a positive difference (fig 1) . When the 14 women with the highest calculated calcium intakes (above 1800 mg/day including the 500 mg supplement) were compared with the 14 with the lowest calculated calcium intakes, no difference was found in the mean change in bone mineral content (-3 9% v -4-1% over two years). Similarly, the 14 women with positive changes in bone mineral content and the 14 with the most negative showed similar initial calcium intakes (1390 mg v 1520 mg including the 500 mg supplement) . Interestingly, the person with the highest calculated calcium intake (2350 mg daily) had a loss of bone mineral content of 4-5% a year no matter how stratification was done. Calcium intake is higher in Denmark than in the United States, and we cannot exclude the possibility that a calcium supplement would benefit women with a calcium depleted diet. On the other hand, our subjects in group 3 (high calcium intake) were definitely losing calcium from their bones (fig 2) . Thus even if the calculated calcium intakes in our study are considered to be inaccurate there is still no evidence of a relation between bone loss and calcium intake.
The question arises whether it is possible to have reduced bone mineral content values without being in negative calcium balance. More than 99% of the body's calcium is located in bones. Our method measured only 1-2% of the total bone mass. At the measuring site, however, the relation between cortical and trabecular bone is similar to the distribution in the whole body.18 19 Measurements of bone mineral content can be done with high accuracy (3%) and precision (1-4% 
